Suppression of inflammation in a mouse model of rheumatoid arthritis using targeted lipase-labile fumagillin prodrug nanoparticles

Biomaterials

Volumn 33, Issue 33, 2012, Pages 8632-8640

  Zhou, Hui fang ^a   Yan, Huimin ^a   Senpan, Angana ^a   Wickline, Samuel A ^a   Pan, Dipanjan ^a   Lanza, Gregory M ^a   Pham, Christine T N ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Arthritis; Drug delivery; Inflammation; Nanoparticles; Prodrug

Indexed keywords

ANGIOGENESIS; ARTHRITIS; BODY WEIGHT; CLINICAL DISEASE; CLINICAL TRANSLATION; DOSE-DEPENDENT MANNER; DRUG RELEASE; EMERGING TECHNOLOGIES; FUMAGILLIN; HUMAN DISEASE; INFLAMMATION; INTEGRINS; MOUSE MODELS; NANOCARRIERS; PRODRUGS; RHEUMATOID ARTHRITIS; TARGETED DELIVERY;

DRUG DELIVERY; DRUG DOSAGE; DRUG PRODUCTS; PATHOLOGY; TIN;

NANOPARTICLES;

ANTIRHEUMATIC AGENT; ASPARTATE AMINOTRANSFERASE; COMPLEMENT COMPONENT C3A; MACROGOL 2000; PRODRUG; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; VITRONECTIN RECEPTOR FUMAGILLIN NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD VESSEL WALL; BODY WEIGHT; CIRCULATION; COMPLEMENT SYSTEM; CONTROLLED STUDY; DISEASE COURSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; DRUG STABILITY; DRUG STRUCTURE; HISTOLOGY; HYDRODYNAMICS; IC 50; IMMUNE RESPONSE; IN VIVO STUDY; INFLAMMATION; INNATE IMMUNITY; LEUKOCYTE; LEUKOCYTE COUNT; LIVER PARENCHYMA; MALE; MICROFLUIDICS; MOUSE; NANOENCAPSULATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; RHEUMATOID ARTHRITIS;

ANIMALS; ARTHRITIS, RHEUMATOID; CYCLOHEXANES; ELECTROPHORESIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATTY ACIDS, UNSATURATED; FLUORESCENT ANTIBODY TECHNIQUE; LIPASE; MALE; MICE; MICE, INBRED C57BL; NANOPARTICLES; SESQUITERPENES;

EID: 84866181821     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.08.005     Document Type: Article

References (52)

1. Costa C., Incio J., Soares R. Angiogenesis and chronic inflammation: cause or consequence?. Angiogenesis 2007, 10:149-166.
2. Szekanecz Z., Koch A.E. Angiogenesis and its targeting in rheumatoid arthritis. Vascul Pharmacol 2009, 51:1-7.
3. Szekanecz Z., Besenyei T., Szentpetery A., Koch A.E. Angiogenesis and vasculogenesis in rheumatoid arthritis. Curr Opin Rheumatol 2010, 22:299-306.
4. Lainer D.T., Brahn E. New antiangiogenic strategies for the treatment of proliferative synovitis. Expert Opin Investig Drugs 2005, 14:1-17.
5. Lainer-Carr D., Brahn E. Angiogenesis inhibition as a therapeutic approach for inflammatory synovitis. Nat Clin Pract Rheumatol 2007, 3:434-442.
6. Arfin S.M., Kendall R.L., Hall L., Weaver L.H., Stewart A.E., Matthews B.W., et al. Eukaryotic methionyl aminopeptidases: two classes of cobalt-dependent enzymes. Proc Natl Acad Sci USA 1995, 92:7714-7718.
7. Sin N., Meng L., Wang M.Q., Wen J.J., Bornmann W.G., Crews C.M. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci USA 1997, 94:6099-6103.
8. Liu S., Widom J., Kemp C.W., Crews C.M., Clardy J. Structure of human methionine aminopeptidase-2 complexed with fumagillin. Science 1998, 282:1324-1327.
9. Wang J., Lou P., Henkin J. Selective inhibition of endothelial cell proliferation by fumagillin is not due to differential expression of methionine aminopeptidases. J Cell Biochem 2000, 77:465-473.
10. Tarze A., Deniaud A., Le Bras M., Maillier E., Molle D., Larochette N., et al. GAPDH, a novel regulator of the pro-apoptotic mitochondrial membrane permeabilization. Oncogene 2007, 26:2606-2620.
11. Ma A.C., Fung T.K., Lin R.H., Chung M.I., Yang D., Ekker S.C., et al. Methionine aminopeptidase 2 is required for HSC initiation and proliferation. Blood 2011, 118:5448-5457.
12. Zhang Y., Yeh J.R., Mara A., Ju R., Hines J.F., Cirone P., et al. A chemical and genetic approach to the mode of action of fumagillin. Chem Biol 2006, 13:1001-1009.
13. Winter P.M., Neubauer A.M., Caruthers S.D., Harris T.D., Robertson J.D., Williams T.A., et al. Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler Thromb Vasc Biol 2006, 26:2103-2109.
14. Schmieder A.H., Caruthers S.D., Zhang H., Williams T.A., Robertson J.D., Wickline S.A., et al. Three-dimensional MR mapping of angiogenesis with alpha5beta1(alpha nu beta3)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model. FASEB J 2008, 22:4179-4189.
15. Winter P.M., Caruthers S.D., Zhang H., Williams T.A., Wickline S.A., Lanza G.M. Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis. JACC Cardiovasc Imaging 2008, 1:624-634.
16. Winter P.M., Schmieder A.H., Caruthers S.D., Keene J.L., Zhang H., Wickline S.A., et al. Minute dosages of alpha(nu)beta3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits. FASEB J 2008, 22:2758-2767.
17. Lanza G.M., Yu X., Winter P.M., Abendschein D.R., Karukstis K.K., Scott M.J., et al. Targeted antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent: implications for rational therapy of restenosis. Circulation 2002, 106:2842-2847.
18. Partlow K.C., Lanza G.M., Wickline S.A. Exploiting lipid raft transport with membrane targeted nanoparticles: a strategy for cytosolic drug delivery. Biomaterials 2008, 29:3367-3375.
19. Soman N.R., Baldwin S.L., Hu G., Marsh J.N., Lanza G.M., Heuser J.E., et al. Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth. J Clin Invest 2009, 119:2830-2842.
20. Zhou H.F., Chan H.W., Wickline S.A., Lanza G.M., Pham C.T. Alphavbeta3-targeted nanotherapy suppresses inflammatory arthritis in mice. FASEB J 2009, 23:2978-2985.
21. Zhou H.F., Hu G., Wickline S.A., Lanza G.M., Pham C.T. Synergistic effect of antiangiogenic nanotherapy combined with methotrexate in the treatment of experimental inflammatory arthritis. Nanomedicine (Lond) 2010, 5:1065-1074.
22. Pan D., Sanyal N., Schmieder A.H., Senpan A., Kim B., Yang X., et al. Anti-angiogenic nanotherapy with lipase-labile Sn-2 fumagillin prodrug. Nanomedicine (Lond) 2012, [Epub ahead of print].
23. Eble T.E., Garrett E.R. Studies on the stability of fumagillin. II. Photolytic degradation of crystalline fumagillin. J Am Pharm Assoc Am Pharm Assoc 1954, 43:536-538.
24. Garrett E.R. Studies on the stability of fumagillin. III. Thermal degradation in the presence and absence of air. J Am Pharm Assoc Am Pharm Assoc 1954, 43:539-543.
25. Garrett E.R., Eble T.E. Studies on the stability of fumagillin. I. Photolytic degradation in alcohol solution. J Am Pharm Assoc Am Pharm Assoc 1954, 43:385-390.
26. Harris T.D., Kalogeropoulos S., Nguyen T., Liu S., Bartis J., Ellars C., et al. Design, synthesis, and evaluation of radiolabeled integrin alpha v beta 3 receptor antagonists for tumor imaging and radiotherapy. Cancer Biother Radiopharm 2003, 18:627-641.
27. Adkison A.M., Raptis S.Z., Kelley D.G., Pham C.T. Dipeptidyl peptidase I activates neutrophil-derived serine proteases and regulates the development of acute experimental arthritis. J Clin Invest 2002, 109:363-371.
28. Alper C.A., Balavitch D. Cobra venom factor: evidence for its being altered cobra C3 (the third component of complement). Science 1976, 191:1275-1276.
29. Meoli D.F., Sadeghi M.M., Krassilnikova S., Bourke B.N., Giordano F.J., Dione D.P., et al. Noninvasive imaging of myocardial angiogenesis following experimental myocardial infarction. J Clin Invest 2004, 113:1684-1691.
30. Winter P.M., Caruthers S.D., Kassner A., Harris T.D., Chinen L.K., Allen J.S., et al. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res 2003, 63:5838-5843.
31. Schmieder A.H., Winter P.M., Caruthers S.D., Harris T.D., Williams T.A., Allen J.S., et al. Molecular MR imaging of melanoma angiogenesis with alphanubeta3-targeted paramagnetic nanoparticles. Magn Reson Med 2005, 53:621-627.
32. Hu G., Lijowski M., Zhang H., Partlow K.C., Caruthers S.D., Kiefer G., et al. Imaging of Vx-2 rabbit tumors with alpha(nu)beta3-integrin-targeted 111In nanoparticles. Int J Cancer 2007, 120:1951-1957.
33. Boles K.S., Schmieder A.H., Koch A.W., Carano R.A., Wu Y., Caruthers S.D., et al. MR angiogenesis imaging with Robo4- vs. alphaVbeta3-targeted nanoparticles in a B16/F10 mouse melanoma model. FASEB J 2010, 24:4262-4270.
34. Kassner A., Thornhill R.E., Liu F., Winter P.M., Caruthers S.D., Wickline S.A., et al. Assessment of tumor angiogenesis: dynamic contrast-enhanced MRI with paramagnetic nanoparticles compared with Gd-DTPA in a rabbit Vx-2 tumor model. Contrast Med Mol Imaging 2010, 5:155-161.
35. Winter P.M., Morawski A.M., Caruthers S.D., Fuhrhop R.W., Zhang H., Williams T.A., et al. Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation 2003, 108:2270-2274.
36. Cai K., Caruthers S.D., Huang W., Williams T.A., Zhang H., Wickline S.A., et al. MR molecular imaging of aortic angiogenesis. JACC Cardiovasc Imaging 2010, 3:824-832.
37. Pan D., Pramanik M., Senpan A., Allen J.S., Zhang H., Wickline S.A., et al. Molecular photoacoustic imaging of angiogenesis with integrin-targeted gold nanobeacons. FASEB J 2011, 25:875-882.
38. Kyburz D., Corr M. The KRN mouse model of inflammatory arthritis. Springer Semin Immunopathol 2003, 25:79-90.
39. Brahn E., Schoettler N., Lee S., Banquerigo M.L. Involution of collagen-induced arthritis with an angiogenesis inhibitor, PPI-2458. J Pharmacol Exp Ther 2009, 329:615-624.
40. Pham C.T., Mitchell L.M., Huang J.L., Lubniewski C.M., Schall O.F., Killgore J.K., et al. Variable antibody-dependent activation of complement by functionalized phospholipid nanoparticle surfaces. J Biol Chem 2011, 286:123-130.
41. Firestein G.S. Starving the synovium: angiogenesis and inflammation in rheumatoid arthritis. J Clin Invest 1999, 103:3-4.
42. Koch A.E. Angiogenesis as a target in rheumatoid arthritis. Ann Rheum Dis 2003, 62(Suppl. 2):ii60-ii70.
43. Klimiuk P.A., Sierakowski S., Domyslawska I., Fiedorczyk M., Chwiecko J. Reduction of soluble adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor levels in serum of rheumatoid arthritis patients following multiple intravenous infusions of infliximab. Arch Immunol Ther Exp 2004, 52:36-42.
44. de Bandt M., Grossin M., Weber A.J., Chopin M., Elbim C., Pla M., et al. Suppression of arthritis and protection from bone destruction by treatment with TNP-470/AGM-1470 in a transgenic mouse model of rheumatoid arthritis. Arthritis Rheum 2000, 43:2056-2063.
45. Bernier S.G., Lazarus D.D., Clark E., Doyle B., Labenski M.T., Thompson C.D., et al. A methionine aminopeptidase-2 inhibitor, PPI-2458, for the treatment of rheumatoid arthritis. Proc Natl Acad Sci USA 2004, 101:10768-10773.
46. Hannig G., Bernier S.G., Hoyt J.G., Doyle B., Clark E., Karp R.M., et al. Suppression of inflammation and structural damage in experimental arthritis through molecular targeted therapy with PPI-2458. Arthritis Rheum 2007, 56:850-860.
47. Davidsen J., Jorgensen K., Andresen T.L., Mouritsen O.G. Secreted phospholipase A(2) as a new enzymatic trigger mechanism for localised liposomal drug release and absorption in diseased tissue. Biochim Biophys Acta 2003, 1609:95-101.
48. Andresen T.L., Davidsen J., Begtrup M., Mouritsen O.G., Jorgensen K. Enzymatic release of antitumor ether lipids by specific phospholipase A2 activation of liposome-forming prodrugs. J Med Chem 2004, 47:1694-1703.
49. Jensen S.S., Andresen T.L., Davidsen J., Hoyrup P., Shnyder S.D., Bibby M.C., et al. Secretory phospholipase A2 as a tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids. Mol Cancer Ther 2004, 3:1451-1458.
50. Andresen T.L., Jensen S.S., Kaasgaard T., Jorgensen K. Triggered activation and release of liposomal prodrugs and drugs in cancer tissue by secretory phospholipase A2. Curr Drug Deliv 2005, 2:353-362.
51. Peters G.H., Moller M.S., Jorgensen K., Ronnholm P., Mikkelsen M., Andresen T.L. Secretory phospholipase A2 hydrolysis of phospholipid analogues is dependent on water accessibility to the active site. J Am Chem Soc 2007, 129:5451-5461.
52. Jorgensen K., Davidsen J., Mouritsen O.G. Biophysical mechanisms of phospholipase A2 activation and their use in liposome-based drug delivery. FEBS Lett 2002, 531:23-27.